BLIS Technologies Limited

BLT

NZBLTE0002S8

Pharmaceuticals

End-of-day quote New Zealand S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
0.017 ^NZD	0.00%		0.00%	-10.53%

Apr. 15	New Zealand Shares Close Flat on Monday; Blis Technologies Upgrades Fiscal 2024 Guidance	MT
Apr. 15	Blis Technologies Upgrades Fiscal 2024 Guidance	MT

BLIS Technologies Limited Provides Latest Guidance for the Year Ended 31 March 2024

April 14, 2024 at 04:30 pm EDT

BLIS Technologies Limited provided latest guidance for the year ended 31 March 2024 is for revenue of $11.5 million. This is an increase on the previous guidance provided on 23rd February 2024 of revenue of around $11.0 million.

Latest news about BLIS Technologies Limited

New Zealand Shares Close Flat on Monday; Blis Technologies Upgrades Fiscal 2024 Guidance	Apr. 15	MT
Blis Technologies Upgrades Fiscal 2024 Guidance	Apr. 14	MT
BLIS Technologies Limited Provides Latest Guidance for the Year Ended 31 March 2024	Apr. 14	CI
Blis Technologies Reports Profitable Third Quarter	Feb. 23	MT
BLIS Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 15	CI
BLIS Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-25	CI
BLIS Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-10	CI
BLIS Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-31	CI
Probi AB Completes First Production Batches of Dairy-Free BLIS K12	22-03-31	CI
BLIS Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2021	21-11-18	CI
Blis Technologies and Probi AB Signs a Licensing and Distribution Agreement	21-07-06	CI
Blis Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2021	21-05-27	CI
Roolife : Launches Blis Technologies’ Online Store on China’s Tmall Global; Shares Fall 4%	21-01-27	MT
RooLife Group Ltd and Blis Technologies Ltd Launches Flagship Store on China's Tmall Global	21-01-26	CI
Blis Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2020	20-11-19	CI
Blis Technologies Limited Announces Retirement of Graeme Boyd from the Board	20-07-22	CI
Blis Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2020	20-05-28	CI
Blis Technologies Launches a New Product UltraBLIS	20-02-02	CI
Blis Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2019	19-11-19	CI
Blis Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2019	19-05-28	CI
BLIS Technologies Limited Announces Retirement of Veronica Aris as A Director	19-05-26	CI
BLIS Technologies Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2019	18-11-14	CI
BLIS Technologies Limited Announces Board Appointments	18-07-26	CI
BLIS Technologies Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2017	17-11-20	CI
BLIS Technologies Limited Provides Earnings Guidance for the Six Months Ending September 30, 2017 and Full Year Ending March 31, 2018	17-10-26	CI

Chart BLIS Technologies Limited

Duration

Period

More charts

Company Profile

Blis Technologies Limited is a New Zealand-based manufacturer of advanced probiotic strains. The Companyâs principal activity is developing healthcare products based on strains of bacteria that produce bacteriocin activity for sale in New Zealand and overseas. It delivers probiotic solutions for specific health targets, including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. Its probiotic portfolio includes BLIS K12, BLIS M18 and BLIS Q24. It sells ingredients and finishes goods to manufacturers and wholesale customers. The BLIS K12 (Streptococcus salivarius K12) is a probiotic to support the mouth and throat. The BLIS M18 (Streptococcus salivarius M18) is a probiotic to support teeth and gum health. The BLIS Q24 balances and restores the skin microbiome, restoring its natural health, clarity and radiance. The Companyâs products are sold throughout New Zealand and in Australia, Asia, Europe and the United States.

Sector

Pharmaceuticals

Calendar

2024-05-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
BLIS TECHNOLOGIES LIMITED	-10.53%	13.09M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.98%	43.48B
OTSUKA HOLDINGS CO., LTD.	+20.67%	22.65B
SANDOZ GROUP AG	+14.56%	14.73B
ZYDUS LIFESCIENCES LIMITED	+44.72%	12.04B
ONO PHARMACEUTICAL CO., LTD.	-8.37%	7.08B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+11.90%	5.47B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-2.27%	4.81B